Silo Pharma extends research pact for Alzheimerās and Stress Induced Anxiety Therapeutics Post published:October 19, 2022 Post category:Press Release
Empyrean Neuroscience Launches with $22M Series A and Genetic Engineering Platform to Advance Pipeline of Neuroactive Compounds Targeting CNS Disorders Post published:October 18, 2022 Post category:Press Release
Small Pharma Reports Fiscal Second Quarter 2023 Highlights Post published:October 15, 2022 Post category:Press Release
Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA Post published:October 15, 2022 Post category:Press Release
Algernon Pharmaceuticals Announces Dr. Rick Strassman author of āDMT: The Spirit Moleculeā to Join CEO Christopher J. Moreau for Keynote Science Address at Wonderland Conference Post published:October 15, 2022 Post category:Press Release
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD Post published:October 13, 2022 Post category:Press Release
FILAMENT HEALTH TO HOST VIRTUAL INVESTOR UPDATE Post published:October 13, 2022 Post category:Press Release
Reunion Neuroscience CEO to Participate on Panel at 2022 Horizons Perspectives on Psychedelics Conference Post published:October 12, 2022 Post category:Press Release
COMPASS Pathways Announces Phase 3 Pivotal Program Design for COMP360 in Treatment Resistant Depression at Capital Markets Day Post published:October 12, 2022 Post category:Press Release
Clearmind Medicine Featured in “Psychedelics Tonight,” Streaming on ALTRD.TV Post published:October 11, 2022 Post category:Press Release